Abstract 312P
Background
The tribal populations throughout India have remained socially and culturally alienated from mainstream Indian society until developmental and conservation activities in tribal areas forced interactions between them. The precancerous oral lesion is a major public health problem among South Indian tribes in Kerala state. The aim of this study was to explore oral health disparities among the underprivileged Paniya and the privileged Kurichiya tribes of Wayanad, South India from the Precancerous oral lesions perspective.
Methods
A cross sectional survey was done among 600 Kurichiya tribes and 400 Paniya tribal populations of Wayanad District, India from January 2013 to June 2013 after approval from the Institutional ethical committee. A pretested structured questionnaire was used to collect data regarding study variables. Oral health survey form was used to record the oromucosal status of the study population after obtaining informed consent.
Results
In this study Precancerous oral lesions was found to be far more prevalent among the underprivileged Paniya tribes than among the privileged Kurichiya tribes (P < 0.0001). The prevalence of leukoplakia was found to be 42% amongst the Paniya tribes. This was much higher than the 2% found among the Kurichiya tribes.Among the Paniya tribes a statistically significant relationship was observed between Precancerous oral lesions and poor access to oral health care (P < 0.001).
Conclusions
The Paniya tribe is a distinct community with their own cultural beliefs, habits, and attitudes. High prevalence of precancerous oral lesions in the underprivileged population was due to tobacco usage and alcohol consumption and lack of awareness regarding the deleterious effects of the products used. Knowledge of these differences can be used to provide appropriate health education programs suitably targeted to reduce the use of the known risk factors for oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract